Home › Funds › SHEETS SMITH WEALTH MANAGEMENT › IBRX

SHEETS SMITH WEALTH MANAGEMENT position in IBRX

IMMUNITYBIO INC · Health Care

SHEETS SMITH WEALTH MANAGEMENT reported holding 512,572 shares of IBRX (IMMUNITYBIO INC) in its Q3 2026 13F filing — a position valued at US$4.8M, representing 0.51% of its reported portfolio and ranking #48 among its reported holdings. SHEETS SMITH WEALTH MANAGEMENT has disclosed IBRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)512.57K sh
Reported value held$4.84M
Portfolio Weight0.51%
First reportedQ3 2023
Last changeHold
Updated2026-10-16

Last updated: 2026-10-16 · Source: SEC EDGAR Form 13F-HR

How SHEETS SMITH WEALTH MANAGEMENT's IBRX position evolved

SHEETS SMITH WEALTH MANAGEMENT first disclosed a stake in IBRX in Q3 2023 at 273,879 shares (US$463K). The position peaked in Q1 2024 at 945,720 shares, worth US$5.1M. Across 13 filings, SHEETS SMITH WEALTH MANAGEMENT increased the stake 1 time(s), trimmed it 5 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 512,572 shares valued at US$4.8M. Notable position changes include a 28% trim in Q4 2023 (shares rose 7% over the following quarter), a 381% increase in Q1 2024 (shares rose 18% over the following quarter), a 30% trim in Q2 2024 (shares fell 41% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 273.88K $462.86K New
Q4 2023 196.68K $987.33K Reduce
Q1 2024 945.72K $5.08M Add
Q2 2024 666.00K $4.21M Reduce
Q3 2024 666.00K $2.48M Hold
Q4 2024 633.98K $1.62M Reduce
Q1 2025 633.48K $1.91M Hold
Q2 2025 633.48K $1.67M Hold
Q3 2025 633.08K $1.56M Hold
Q4 2025 631.98K $1.25M Hold
Q1 2026 552.02K $4.23M Reduce
Q2 2026 512.57K $4.49M Reduce
Q3 2026 512.57K $4.84M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IBRX and 13F data

IBRX (IMMUNITYBIO INC) is a Health Care company. 68 other funds we track also report a position in IBRX — the largest reported positions include GREAT POINT PARTNERS LLC (US$26.3M), VESTOR CAPITAL, LLC (US$12.1M), Sound Capital Solutions LLC (US$9.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IBRX

All IBRX fund holders →

FAQ

How long has SHEETS SMITH WEALTH MANAGEMENT held IBRX?

SHEETS SMITH WEALTH MANAGEMENT has disclosed IBRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is SHEETS SMITH WEALTH MANAGEMENT's current position in IBRX?

As of Q3 2026, SHEETS SMITH WEALTH MANAGEMENT holds 512.57K shares of IBRX (IMMUNITYBIO INC), valued at $4.84M, representing 0.51% of its reported portfolio and ranking #48.

Has SHEETS SMITH WEALTH MANAGEMENT been buying or selling IBRX?

In the latest 13F filing (Q3 2026), SHEETS SMITH WEALTH MANAGEMENT held unchanged its position in IBRX. The position peaked in Q1 2024 at 945.72K shares.

Which other funds hold IBRX?

Other major institutional holders of IBRX include GREAT POINT PARTNERS LLC, VESTOR CAPITAL, LLC, Sound Capital Solutions LLC, among 68 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.